This is a community-generated profile. If you work at Replimune Group, to claim it.
DiscoverStartupsReplimune Group
Replimune Group company logo
Replimune Group develops next-generation oncolytic immunotherapies for cancer treatment201-500 Employees
  • Recently funded
    Raised funding in the past six months

Replimune Group careers

Replimune Group develops next-generation oncolytic immunotherapies for cancer treatment
Replimune is a clinical-stage biotechnology company that develops oncolytic immunotherapies designed to trigger a systemic anti-tumor immune response. Using its proprietary RPx platform based on an engineered herpes simplex virus 1 (HSV-1) backbone, the company aims to treat a broad range of solid tumors. Its first FDA-approved therapy, TUDRIQEV, is indicated for patients with advanced melanoma.

Director, Data Analytics and Reporting

Remote only • Woburn, Massachusetts
$201k – $260k
1 month ago
Valuation

$0

Funded over

1 round

Latest round

Seed (Aug 2026)